Serum Level of Clusterin and Its Density in Men with Prostate Cancer as Novel Biomarkers Reflecting Disease Extension

Urology

Volumn 75, Issue 2, 2010, Pages 454-459

  Miyake, Hideaki ^a   Muramaki, Mototsugu ^a   Furukawa, Junya ^a   Kurahashi, Toshifumi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CLUSTERIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; ENZYME IMMUNOASSAY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CLUSTERIN; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 75349105630     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.08.029     Document Type: Article

References (24)

1. Trougakos I.P., and Gonos E.S. Clusterin/apolipoproyein J in human aging and cancer. Int J Biochem Cell Biol 34 (2002) 1430-1448
2. Gleave M., and Chi K.N. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann NY Acad Sci 1058 (2005) 1-15
3. Miyake H., Hara I., and Gleave M.E. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol 12 (2005) 785-794
4. Miyake H., Hara I., Fujisawa M., et al. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs 15 (2006) 507-517
5. Steinberg J., Oyasu R., Lang S., et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3 (1997) 1707-1711
6. July L.V., Akbari M., Zellweger T., et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 (2002) 179-188
7. Pins M.R., Fiadjoe J.E., Korley F., et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 7 (2004) 243-248
8. Miyake H., Muramaki M., Kurahashi T., et al. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 68 (2006) 609-614
9. Miyake H., Yamanaka K., Muramaki M., et al. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep 14 (2005) 1371-1375
10. Doustjalali S.R., Yusof R., Yip C.H., et al. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis 25 (2004) 2392-2401
11. Stejskal D., and Fiala R.R. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 53 (2006) 343-346
12. Miyake H., Harada K., Inoue T., et al. Additional sampling of the dorsal apex on systematic prostate biopsy: impact on early detection of prostate cancer. Urology 69 (2007) 738-742
13. Redondo M., Villar E., Torres-Muñoz J., et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol 157 (2000) 393-399
14. Kurahashi T., Muramaki M., Yamanaka K., et al. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 96 (2005) 895-899
15. Xie D., Lau S.H., Sham J.S., et al. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 103 (2005) 277-283
16. Watari H., Ohta Y., Hassan M.K., et al. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol 108 (2008) 527-532
17. Ravery V., Chastang C., Toublanc M., et al. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol 37 (2000) 449-455
18. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603
19. Ohori M., Kattan M.W., Koh H., et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 171 (2004) 1844-1849
20. Gao X., Ren S., Lu X., et al. The newer the better?. Comparison of the 1997 and 2001 partin tables for pathologic stage prediction of prostate cancer in China. Urology 72 (2008) 1096-1101
21. Quinn D.I., Henshall S.M., Haynes A.M., et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 19 (2001) 3692-3705
22. Karakiewicz P.I., Eastham J.A., Graefen M., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 66 (2005) 1245-1250
23. Chi K.N., Siu L.L., Hirte H., et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14 (2008) 833-839
24. Chi K.N., Eisenhauer E., Fazli L., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296